Andrea Paladini, Marco Spinetta, Roberta Matheoud, Andrea D'Alessio, Miriana Sassone, Riccardo Di Fiore, Carolina Coda, Serena Carriero, Pierpaolo Biondetti, Domenico Laganà, Roberto Minici, Vittorio Semeraro, Gian Mauro Sacchetti, Gianpaolo Carrafiello, Giuseppe Guzzardi
Background : Introduced in the latest BCLC 2022, endovascular trans-arterial radioembolization (TARE) has an important role in the treatment of unresectable hepatocellular carcinoma (HCC) as a "bridge" or "downstaging" of disease. The evolution of TARE technology allows a more flexible and personalized target treatment, based on the anatomy and vascular characteristics of each HCC. The flex-dose delivery program is part of this perspective, which allows us to adjust the dose and its radio-embolizing power in relation to the size and type of cancer and to split the therapeutic dose of Y90 in different injections (split-bolus)...
April 10, 2024: Journal of Clinical Medicine